DNMT3A and acute myeloid leukemia: AML patients with the R882 mutations revealed global hypomethylation, as compared to AML patients without DNMT3A mutation (Fig. 5a): 7976 CpGs were more than 20% hypomethylated in R882 patients, whereas only 10 CpGs were 20% higher methylated.